{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:53:34Z","timestamp":1792068814878,"version":"4.4.0"},"reference-count":32,"publisher":"Royal College of Psychiatrists","issue":"5","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["BJPsych open"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec id=\"S2056472424007476_sec_a1\">\n\t    <jats:title>Background<\/jats:title>\n\t    <jats:p>Pharmacological treatment options for patients with dementia owing to Alzheimer's disease are limited to symptomatic therapy. Recently, the US Food and Drug Administration approved the monoclonal antibody lecanemab for the treatment of amyloid-positive patients with mild cognitive impairment (MCI) and early Alzheimer\u00b4s dementia. European approval is expected in 2024. Data on the applicability and eligibility for treatment with anti-amyloid monoclonal antibodies outside of a study population are lacking.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2056472424007476_sec_a2\">\n\t    <jats:title>Aims<\/jats:title>\n\t    <jats:p>This study examined eligibility criteria for lecanemab in a real-world memory clinic population between 1 January 2022 and 31 July 2023.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2056472424007476_sec_a3\" sec-type=\"methods\">\n\t    <jats:title>Method<\/jats:title>\n\t    <jats:p>We conducted a retrospective, single-centre study applying the clinical trial eligibility criteria for lecanemab to out-patients of a specialised psychiatric memory clinic. Eligibility for anti-amyloid treatment was assessed following the phase 3 inclusion and exclusion criteria and the published recommendations for lecanemab.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2056472424007476_sec_a4\" sec-type=\"results\">\n\t    <jats:title>Results<\/jats:title>\n\t    <jats:p>The study population consisted of 587 out-patients. Two-thirds were diagnosed with Alzheimer's disease (probable or possible Alzheimer's disease dementia in 43.6% of cases, <jats:italic>n<\/jats:italic> = 256) or MCI (23%, <jats:italic>n<\/jats:italic> = 135), and 33.4% (<jats:italic>n<\/jats:italic> = 196) were diagnosed with dementia or neurocognitive disorder owing to another aetiology. Applying all lecanemab eligibility criteria, 11 (4.3%) patients with dementia and two (1.5%) patients with MCI would have been eligible for treatment with this compound, whereas 13 dementia (5.1%) and 14 (10.4%) MCI patients met clinical inclusion criteria, but had no available amyloid status.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2056472424007476_sec_a5\" sec-type=\"conclusions\">\n\t    <jats:title>Conclusions<\/jats:title>\n\t    <jats:p>Even in a memory clinic with a good infrastructure and sufficient facilities for dementia diagnostics, most patients do not meet the eligibility criteria for treatment with lecanemab.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1192\/bjo.2024.747","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T07:55:09Z","timestamp":1727078109000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":18,"title":["Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population"],"prefix":"10.1192","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9613-9485","authenticated-orcid":false,"given":"Michaela","family":"Defrancesco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke R.","family":"Gizewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mangesius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik","family":"Galijasevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Virgolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Marksteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Jehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Doganyigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"S2056472424007476_ref1","unstructured":"1 Cavazzoni, P . FDA's Decision to Approve New Treatment for Alzheimer's Disease. US Food and Drug Administration, 2021 (https:\/\/www.fda.gov\/drugs\/our-perspective\/fdas-decision-approve-new-treatment-alzheimers-disease)."},{"key":"S2056472424007476_ref23","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5789"},{"key":"S2056472424007476_ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207156"},{"key":"S2056472424007476_ref17","first-page":"362","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"S2056472424007476_ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.4078"},{"key":"S2056472424007476_ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43933-5"},{"key":"S2056472424007476_ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.12.1985"},{"key":"S2056472424007476_ref13","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"S2056472424007476_ref12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2412-a"},{"key":"S2056472424007476_ref26","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201043"},{"key":"S2056472424007476_ref15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.5_Suppl_6.10S"},{"key":"S2056472424007476_ref24","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17390"},{"key":"S2056472424007476_ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"S2056472424007476_ref27","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17530"},{"key":"S2056472424007476_ref32","first-page":"CD001190","article-title":"Donepezil for dementia due to Alzheimer's disease","volume":"6","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"S2056472424007476_ref20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.10.967"},{"key":"S2056472424007476_ref18","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.149.2.351"},{"key":"S2056472424007476_ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15286"},{"key":"S2056472424007476_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(82)90033-4"},{"key":"S2056472424007476_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"S2056472424007476_ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2111320"},{"key":"S2056472424007476_ref29","first-page":"398","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"S2056472424007476_ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.3061"},{"key":"S2056472424007476_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2021.05.080"},{"key":"S2056472424007476_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"S2056472424007476_ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332311"},{"key":"S2056472424007476_ref19","doi-asserted-by":"publisher","DOI":"10.1007\/BF00868807"},{"key":"S2056472424007476_ref25","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2023.166"},{"key":"S2056472424007476_ref21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"S2056472424007476_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102290"},{"key":"S2056472424007476_ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"S2056472424007476_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"}],"container-title":["BJPsych Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2056472424007476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T07:55:14Z","timestamp":1727078114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2056472424007476\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["S2056472424007476"],"URL":"https:\/\/doi.org\/10.1192\/bjo.2024.747","relation":{},"ISSN":["2056-4724"],"issn-type":[{"value":"2056-4724","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e160"}}